Novigenix, a leader in AI-driven healthcare solutions, has today announced the approval of a Eurostars grant for the MYeloid SIGNATUREs (MY-SIGNATURE) project. This prestigious grant, totaling a consortium budget of €1.75 million, will support the development of MYELO-SCAN, the world’s first liquid biopsy test designed to predict intratumoral myeloid-derived suppressor cell (MDSC) infiltration in metastatic castration-resistant prostate cancer (mCRPC) patients. 

Novigenix will lead the MY-SIGNATURE consortiumin collaboration with the Dutch subsidiary of Crown Bioscience and the “Precision Medicine in Genito-Urinary Cancers” research group led by Dr. Niven Mehra, Associate Professor in Medical Oncology at Radboud University and a key opinion leader in immuno-oncology. The project will start on October 1, 2024. The MYELO-SCAN test aims to revolutionize precision therapy by developing a validated prototype for predicting MDSC infiltration, a critical factor in treatment resistance for mCRPC patients. 

Dr. Niven Mehra said, “This project is a significant step forward in the field of precision medicine. By developing a reliable biomarker for MDSCs, MYELO-SCAN will address a critical gap in our current capabilities and offer new hope for patients facing the challenges of treatment resistance.”  

Prostate cancer causes approximately 110,000 fatalities each year in the EU.  MY-SIGNATURE will address the urgent need for robust biomarkers to optimize treatment and overcome resistance to current therapies.  

Dr. Pedro Romero, Chief Medical & Scientific Officer at Novigenix, said, “We are excited to embark on this innovative project, which has the potential to significantly improve patient outcomes in metastatic castration-resistant prostate cancer. The MYELO-SCAN test represents a major advancement in our ability to stratify patients more effectively and tailor treatments to those most likely to benefit.” 

The consortium anticipates that MYELO-SCAN will be ready for clinical validation by Q4 2026, CE-marking following shortly thereafter. With projected revenues of €1.14 billion, this project promises substantial economic opportunities in addition to the significant clinical impact .